Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain

In brief

This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.

Key facts

Study ID

NCT07539623

Run by

Icahn School of Medicine at Mount Sinai

People needed

235

Starts

2026-05-01

Expected to finish

2026-12-22

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be eligible to participate in this study, an individual must meet all of the following criteria:
• Adults 18-85 years old
• Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)
• All genders

You may not qualify if…

• Any individual who meets any of the following criteria will be excluded from participation in this study:
• ASA Class V
• Urgent or emergent surgery
• Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)
• History of substance use disorder or chronic opioid use
• Reoperation
• Patient refusal or inability to consent
• Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and
• Clarithromycin)
• Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)

Where it is running

• Mount Sinai Morningside — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.